Chronic myeloid leukemia — before and after imatinib (Third part)
Imatinib (IM) appearance has changed approaches to chronic myeloid leukemia (CML) therapy. Second generation tyrosine kinase inhibitors (TKI) — nilotinib and dasatinib, developed soon after IM, and are already widely used in CML patients with inefficiency or intolerance of them. Considering availabi...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
ABV-press
2022-11-01
|
| Series: | Онкогематология |
| Subjects: | |
| Online Access: | https://oncohematology.abvpress.ru/ongm/article/view/604 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849690011284275200 |
|---|---|
| author | E. G. Lomaia M. Yu. Konopleva E. G. Romanova A. Yu. Zaritzkiy |
| author_facet | E. G. Lomaia M. Yu. Konopleva E. G. Romanova A. Yu. Zaritzkiy |
| author_sort | E. G. Lomaia |
| collection | DOAJ |
| description | Imatinib (IM) appearance has changed approaches to chronic myeloid leukemia (CML) therapy. Second generation tyrosine kinase inhibitors (TKI) — nilotinib and dasatinib, developed soon after IM, and are already widely used in CML patients with inefficiency or intolerance of them. Considering availability in clinical practice of tree TKI, allogeneic hematopoietic stem cell transplantation (HSCT) and new preparations development, there is a real treatment of all patients with CML, which was recently considered as fatal disease. In first two parts of article general information about CML, issues concerning HSCT, TKI mechanisms of action and safety are discussed. In this part TKI therapy efficacy and modern treatment recommendation for CML patients in different phases are presented. |
| format | Article |
| id | doaj-art-202d0cb6000e4d1db51acf67934d8ead |
| institution | DOAJ |
| issn | 1818-8346 2413-4023 |
| language | Russian |
| publishDate | 2022-11-01 |
| publisher | ABV-press |
| record_format | Article |
| series | Онкогематология |
| spelling | doaj-art-202d0cb6000e4d1db51acf67934d8ead2025-08-20T03:21:27ZrusABV-pressОнкогематология1818-83462413-40232022-11-0101520481Chronic myeloid leukemia — before and after imatinib (Third part)E. G. Lomaia0M. Yu. Konopleva1E. G. Romanova2A. Yu. Zaritzkiy3Federal Almazov hearth, blood and endocrinology CentreFederal Almazov hearth, blood and endocrinology CentreFederal Almazov hearth, blood and endocrinology CentreFederal Almazov hearth, blood and endocrinology CentreImatinib (IM) appearance has changed approaches to chronic myeloid leukemia (CML) therapy. Second generation tyrosine kinase inhibitors (TKI) — nilotinib and dasatinib, developed soon after IM, and are already widely used in CML patients with inefficiency or intolerance of them. Considering availability in clinical practice of tree TKI, allogeneic hematopoietic stem cell transplantation (HSCT) and new preparations development, there is a real treatment of all patients with CML, which was recently considered as fatal disease. In first two parts of article general information about CML, issues concerning HSCT, TKI mechanisms of action and safety are discussed. In this part TKI therapy efficacy and modern treatment recommendation for CML patients in different phases are presented.https://oncohematology.abvpress.ru/ongm/article/view/604chronic myeloid leukemiatyrosine kinase inhibitorsimatinibnilotinibdasatinib |
| spellingShingle | E. G. Lomaia M. Yu. Konopleva E. G. Romanova A. Yu. Zaritzkiy Chronic myeloid leukemia — before and after imatinib (Third part) Онкогематология chronic myeloid leukemia tyrosine kinase inhibitors imatinib nilotinib dasatinib |
| title | Chronic myeloid leukemia — before and after imatinib (Third part) |
| title_full | Chronic myeloid leukemia — before and after imatinib (Third part) |
| title_fullStr | Chronic myeloid leukemia — before and after imatinib (Third part) |
| title_full_unstemmed | Chronic myeloid leukemia — before and after imatinib (Third part) |
| title_short | Chronic myeloid leukemia — before and after imatinib (Third part) |
| title_sort | chronic myeloid leukemia before and after imatinib third part |
| topic | chronic myeloid leukemia tyrosine kinase inhibitors imatinib nilotinib dasatinib |
| url | https://oncohematology.abvpress.ru/ongm/article/view/604 |
| work_keys_str_mv | AT eglomaia chronicmyeloidleukemiabeforeandafterimatinibthirdpart AT myukonopleva chronicmyeloidleukemiabeforeandafterimatinibthirdpart AT egromanova chronicmyeloidleukemiabeforeandafterimatinibthirdpart AT ayuzaritzkiy chronicmyeloidleukemiabeforeandafterimatinibthirdpart |